CDK9 and lymphoma: A high RIS score was also reported for the positive regulation of the reactive oxygen species (ROS) metabolic process pathway (GO:2000379) associated with the DB cell line (lymphoma) when administered with Dinaciclib (an inhibitor of CDK1, CDK2, CDK5, and CDK9).